August 2024 in “Cosmetics” This review discusses genetic and pharmacogenetic insights, along with RNA interference technologies, for developing personalized therapies for androgenetic alopecia, yet presents no new clinical results.
February 2026 in “Frontiers in Pharmacology” This review suggests a shift toward genetically informed treatments for male pattern hair loss by integrating genetic insights and pharmacogenetic markers into therapeutic decision-making.
16 citations
,
September 2014 in “International Journal of Biological Markers” This study found that the less common CAG-rs4045402 and GGN-rs3138869 polymorphisms were more frequent in patients with post-finasteride syndrome and androgenetic alopecia, suggesting a genetic predisposition to AGA development.
September 2025 in “Cosmetics” This study found that using a pharmacogenetic panel with 26 SNPs can improve treatment outcomes for androgenetic alopecia, as overall response rates to minoxidil, finasteride, and dutasteride were high, and specific genetic markers predicted poor responses to these drugs.
20 citations
,
August 2014 in “Talanta” This study developed a novel method to simultaneously measure finasteride, dutasteride, and related biomarkers in serum, finding that both drugs lowered DHT levels while increasing substrate concentrations.